ATS publishes clinical practice guidelines on sleep apnea and driving

June 1, 2013, University Hospitals Case Medical Center

The American Thoracic Society has released new clinical practice guidelines on sleep apnea, sleepiness, and driving risk on non-commercial drivers.

The new guidelines, which are an update of a 1994 ATS statement on this topic, appear in the June 1, 2013 American Journal of Respiratory and Critical Care Medicine.

"Up to 20 percent of crashes that occur on monotonous roads can be attributed to sleepiness, and the most common medical cause of is obstructive sleep apnea (OSA)," said Kingman P. Strohl, MD, program director, , University Hospitals Case Medical Center, director of the Center for Research at Case Western Reserve University and chair of the committee that drafted the guidelines. "With these new guidelines, we aimed to provide healthcare practitioners with a framework for the assessment and management of sleepy driving in the evaluation of OSA."

The guidelines' recommendations include the following:

  • All patients undergoing initial evaluation for suspected or confirmed OSA should be asked about daytime sleepiness and recent unintended or near-misses attributable to sleepiness, fatigue, or inattention. Patients with these characteristics are considered high-risk drivers and should be warned about the potential risk of driving until effective therapy is initiated.
  • Additional information that should be elicited during initial evaluation for suspected or confirmed OSA includes the clinical severity of the OSA and treatment that the patient has received, including . Adherence and response to therapy should be assessed at subsequent visits. Drowsy driving risk should be reassessed at subsequent visits if it was initially increased.
  • For patients in whom there is a high clinical suspicion of OSA and who have been deemed high-risk drivers:

    • Polysomnography should be performed and, if indicated, treatment initiated as soon as possible, rather than delayed until convenient. For patients with no comorbidities and a high clinical suspicion for OSA, at-home portable monitoring is a reasonable alternative to polysomnography.
    • Empiric continuous positive airway (CPAP) should not be used for the sole purpose of reducing driving risk.

  • For patients with confirmed OSA who have been deemed high-risk drivers, CPAP therapy to reduce driving risk is recommended, rather than no treatment.
  • For patients with suspected or confirmed OSA who have been deemed high-risk drivers, stimulant medications for the sole purpose of reducing driving risk are not recommended.
  • Opportunities to improve clinical practice include the following:

    • Clinicians should develop a practice-based plan to inform patients and their families about drowsy driving and other risks of excessive sleepiness, as well as behavioral methods that may reduce those risks.
    • Clinicians should routinely inquire in patients suspected with OSA about non-OSA causes of excessive daytime sleepiness, co-morbid neurocognitive impairments, and diminished physical skills, which may additively contribute to crash risk and affect the efficacy of sleep apnea treatment.
    • Clinicians should familiarize themselves with local and state statutes or regulations regarding the compulsory reporting of high-risk drivers with OSA.
"Addressing the issue of drowsy requires the combined effort of physicians, patients, and policy makers," said Dr. Strohl. "The assessment for sleepiness before and with treatment of OSA, as outlined in these new guidelines, is an essential part of these joint efforts."

Explore further: CPAP treatment effective in patients with milder obstructive sleep apnea and daytime sleepiness

More information: www.thoracic.org/media/press-r … resources/Strohl.pdf

Related Stories

CPAP treatment effective in patients with milder obstructive sleep apnea and daytime sleepiness

July 20, 2012
Continuous positive airway pressure (CPAP), well established as an effective treatment for severe obstructive sleep apnea (OSA), is also effective in patients with mild and moderately severe OSA and daytime sleepiness, according ...

Obstructive sleep apnea associated with less visceral fat accumulation in women than men

May 22, 2013
A new study from researchers in Japan indicates that obstructive sleep apnea (OSA) is independently associated with visceral (abdominal) fat accumulation only in men, perhaps explaining gender differences in the impact of ...

Researchers identify a potential new risk for sleep apnea: Asthma

May 19, 2013
Researchers at the University of Wisconsin have identified a potential new risk factor for obstructive sleep apnea: asthma. Using data from the National Institutes of Health (Heart, Lung, and Blood Institute)-funded Wisconsin ...

OSA increases cardiovascular mortality in the elderly

September 7, 2012
Untreated severe obstructive sleep apnea (OSA) is associated with an increased risk of cardiovascular mortality in the elderly, and adequate treatment with continuous positive airway pressure (CPAP) may significantly reduce ...

Bariatric patients with obstructive sleep apnea fail to show symptoms

August 9, 2012
A Rhode Island Hospital researcher has found that the majority of bariatric surgery patients being treated for obesity have clinically significant obstructive sleep apnea (OSA), but report fewer symptoms than other sleep ...

Recommended for you

Synthetic cannabinoid reduces sleep apnea

November 29, 2017
A synthetic version of a molecule found in the cannabis plant was safe and effective in treating obstructive sleep apnea in the first large, multi-site study of a drug for the sleep disorder funded by the National Institutes ...

Sleeping through the snoring: Researchers identify neurons that rouse the brain to breathe

November 2, 2017
A common and potentially serious sleep disorder, obstructive sleep apnea affects at least one quarter of U.S. adults and is linked to increased risk of diabetes, obesity and cardiovascular disease. In a paper published today ...

Remede system approved for sleep apnea

October 9, 2017
(HealthDay)—The Remede sleep system, an implanted device that treats central sleep apnea by activating a nerve that sends signals to the diaphragm to stimulate breathing, has been approved by the U.S. Food and Drug Administration.

Inflammation may precede sleep apnea, could be treatment target

September 1, 2017
Inflammation is traditionally thought of as a symptom of sleep apnea, but it might actually precede the disorder, potentially opening the door for new ways to treat and predict sleep apnea, according to researchers.

More evidence: Untreated sleep apnea shown to raise metabolic and cardiovascular stress

August 31, 2017
Sleep apnea, left untreated for even a few days, can increase blood sugar and fat levels, stress hormones and blood pressure, according to a new study of sleeping subjects. A report of the study's findings, published in the ...

Sleep patterns contribute to racial differences in disease risk

August 18, 2017
Poor sleep patterns could explain, in part, the differences in the risk of cardiometabolic disease between African-Americans and European-Americans, according to a new study published in Proceedings of the National Academy ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.